[60] In 2015, it was the eighth-largest drug company in the world based on sales revenue. If you are in the United States and would like additional information regarding AstraZeneca products, or you are a third party with an offer of services for AstraZeneca, you can contact the AstraZeneca Information Center by phone at 1-800-236-9933 (Monday - Friday 8 a.m. - 6 p.m. You can opt out for email subscriptions at any time. Astra acquired the experimental antibiotic NXL-104 (CEF104) (CAZ-AVI) through this acquisition. A spokeswoman for Skanska told the Cambridge Independent: “AstraZeneca (AZ) and Skanska UK have agreed to end their association in relation to the AZ headquarters building on the Cambridge Biomedical Campus. With more than $24 billion in revenue in 2019 and 70,600 employees, the Cambridge-based drugmaker continues to rank among the largest drug companies in the world. About AstraZeneca in Cambridge. It will also conduct research on respiratory, inflammation and autoimmune diseases, cardiovascular and metabolic diseases, as well as conditions of the central nervous system. AstraZeneca is headquartered in Cambridge, United Kingdom and has 119 office locations across 65 countries. AstraZeneca es una empresa farmacéutica global con sede en Cambridge, Reino Unido.Es la quinta empresa farmacéutica del mundo medido por ingresos y tiene operaciones en más de 100 países. for New US Headquarters", "AstraZeneca's Iressa FDA committee judgement expected tomorrow", AstraZeneca buys biotech company for £120m, AstraZeneca and Astex ally for anticancer agents, AstraZeneca agrees to buy Arrow Therapeutics for US$150M, AstraZeneca seeks a remedy for its patent pain, "AstraZeneca to pay $15.2B to purchase rival MedImmune; Deal sees London-based drugmaker take on debt for the first time in order to fill product line", AstraZeneca Buys MedImmune for US$ 15.6 Billion, "AstraZeneca To Acquire Infection Research Company Novexel And Expand Collaboration With Forest Laboratories", AstraZeneca and Amgen collaborate on treatments for inflammatory diseases, AstraZeneca Reaches $1.26 Billion Deal for Ardea Biosciences, "AstraZeneca to pay £2.2bn towards 'joint venture' diabetes deal", "Bristol-Myers to buy Amylin for about US$5.3 billion", "AstraZeneca to axe 1,600 jobs in overhaul of drug R&D", "AstraZeneca cuts UK headcount and moves to Cambridge", AstraZeneca outlines strategy to return to growth and achieve scientific leadership, "AstraZeneca buys oncology-focused Spirogen for up to $440 million", "AstraZeneca rejects Pfizer 'final' takeover offer, triggers major drop in shares", "AstraZeneca and MTPC come together for research on diabetic nephropathy drugs", "GEN - News Highlights:Lilly Joins AstraZeneca to Co-Develop BACE Inhibitor for Alzheimer's", "GEN - News Highlights:AstraZeneca Bolsters Oncology Focus with Definiens Purchase, Trial Collaboration", "GEN - News Highlights:Aegerion Snaps Up Rare Disease Drug from AstraZeneca for US$325M+", "AstraZeneca Wins Approval for Ovarian-Cancer Drug It Had Dropped", "GEN - News Highlights:AstraZeneca Buys U.S., Canadian Rights to Actavis Respiratory Drugs for $600M+", "GEN - News Highlights:AstraZeneca, Orca Launch Up-to-$122.5M Autoimmune Collaboration", "GEN - News Highlights:AstraZeneca Launches $40M Early-Stage Anti-Infectives R& Unit", "AstraZeneca underwrites Cambridge-Sweden flights | Business Weekly | Technology News | Business news | Cambridge and the East of England", "GEN - News Highlights:For Up-to-$825M, Daiichi Sankyo Joins AstraZeneca in Co-Marketing Movantik", "GEN - News Highlights:AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips", "GEN - News Highlights:MedImmune, Juno Team Up to Study Cancer Immunotherapy Combo", "Eolas and AstraZeneca Agree to Develop Orexin-1 Receptor Antagonist for Multiple Indications", "AstraZeneca Selling Ex-U.S. Entocort Rights to Tillotts Pharma", "Genzyme to Buy Caprelsa from AstraZeneca for Up to $300M", "AstraZeneca to Develop Heptares Cancer Candidate in $510M+ Collaboration", "MedImmune Licenses Inovio Cancer Vaccine for Up to $727.5M - GEN News Highlights - GEN", "Valeant Licenses Brodalumab from AstraZeneca for Up to $445M", "AstraZeneca auctions off troubled psoriasis drug to Valeant in $445M deal", "AstraZeneca acquires ZS Pharma in $2.7 billion deal", "Takeda to Sell Its Respiratory Portfolio to AstraZeneca", "AstraZeneca Takes Majority Stake in Acerta for $4B", "AstraZeneca chief demands clarity on post-Brexit landscape", "AstraZeneca has started preparations for hard Brexit, including operations move from UK", "Brexit ger fler Astra Zenecajobb i Sverige", "AstraZeneca spins off autoimmune drugs into new biotech company", "AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal", "AstraZeneca schließt die Produktion in Wedel - Hamburger Abendblatt", "AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm", "AstraZeneca sells Atacand rights to Cheplapharm", "AstraZeneca divests global rights to Movantik", "A new pharma king? [76], In September, AstraZeneca announced it had acquired the preclinical oral PCSK9 inhibitor programme from Dogma Therapeutics for an undisclosed sum. It is home to one of AstraZeneca’s three strategic, global R&D Centres, alongside Gothenburg and Gaithersburg, and plays a central role in our mission to deliver life-changing medicines to patients. AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. The AstraZeneca campus on the CBC will comprise a north and south plot. Lonza announced the expansion of its bioconjugation facility at its Visp site in Switzerland in December 2020. So much so, in fact, that in 2016 AstraZeneca moved its global headquarters to Cambridge to build on its partnership with the University and with the other research institutions, hospitals and businesses which make Cambridge the most successful life-sciences cluster in Europe. [67], In September 2019, the company announced that it would cease drug production at its German headquarters in Wedel, leading to the loss of 175 jobs by the end of 2021. INO-3112 targets Human papillomavirus types 16 and 18. They have been investigating the biology of lung cell development and working with AstraZeneca’s drug discovery scientists to understand how to speed that process up. ... Once completed, more than 2,000 AstraZeneca and MedImmune R&D science jobs will be on the CBC site, delivering more knowledge sharing, skills and expertise – and ultimately for pushing the boundaries of science.